Epigenomics AG

http://www.epigenomics.com

11.01.2010 – 16:55
EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S.
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. New Products/Molecular diagnostics 11.01.2010 Berlin, January 11, 2010 - Epigenomics AG (ISIN: DE000A0BVT96), a ...
plus
21.12.2009 – 08:02
EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Strategic Partner Abbott Launches Colorectal Cancer Blood Test in Europe and Asia/Pacific
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Licensing Agreements/Molecular diagnostics 21.12.2009 Berlin, December 21, 2009 - Epigenomics AG (ISIN: ...
plus
17.12.2009 – 11:19
EANS-News: Epigenomics AG: PRESEPT Study Subject Enrollment Successfully Completed
7,852 subjects prospectively enrolled including more than 50 cancer cases Blood samples selected for testing by independent biostatistics group Septin9 testing in three independent laboratories on track; majority of samples tested Completion of PRESEPT Study and reporting of top-line results expected for early 2010 Corporate news transmitted by ...
plus
10.11.2009 – 08:31
EANS-News: Epigenomics AG Reports Q3 and Nine Months 2009 Results
Key Figures 9M 2009 Revenue, EBIT and net loss significantly improved * Revenue: EUR 3.2 million in 9M 2009, up by 77% (9M 2008: EUR 1.8 million) * EBIT: EUR - 7.1 million in 9M 2009, improved by 17% (9M 2008: EUR -8.5 million) * Net loss: EUR - 7.1 million in 9M 2009, decreased by 13% (9M 2008: EUR -8.1 million) * Liquid assets: EUR 9.5 million at end of September 2009 (31/12/2008: EUR 12.1 million) ...
plus
02.11.2009 – 10:01
EANS-News: Epigenomics AG: U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Licensing Agreements/Molecular Diagnostics Press release, Berlin, Germany, and Seattle, WA, USA, November 2, 2009 (euro adhoc) - The cancer molecular diagnostics ...
plus
08.10.2009 – 13:31
EANS-News: Epigenomics AG Initiates Testing of Blood Plasma Samples from PRESEPT Study in Three Independent Clinical Laboratories
PRESEPT Study evaluates clinical performance and health economic benefit of colorectal cancer screening with mSEPT9 blood test Quest Diagnostics, ARUP Laboratories, and Charité - Universitätsmedizin Berlin selected to test mSEPT9 biomarker in blood plasma samples from PRESEPT Study subjects ...
plus
06.10.2009 – 08:46
EANS-News: Epigenomics AG Launches its Epi proColon Product in Europe - the First Ever In Vitro Diagnostic Blood Test for Colorectal Cancer Early Detection
Epi proColon is the first CE-marked test in accordance with European IVD regulations for the early detection of colorectal cancer in a simple blood draw Epi proColon finds two thirds of cancers at early, curable disease stages in final performance evaluation study Epi proColon will now be made available to ...
plus
06.10.2009 – 08:04
EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act) Epigenomics AG Launches Colorectal Cancer Blood Test Epi proColon in Europe
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. New Products/Molecular diagnostics 06.10.2009 Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular ...
plus
21.09.2009 – 10:01
EANS-News: Epigenomics AG: First Blood Test for Colorectal Cancer Available in Germany
First diagnostic laboratories start offering testing based on Epigenomics' Septin9 biomarker on October 1st Test is able to detect colorectal cancer in a simple blood draw Company hosts press conference at ECCO/ESMO Congress in Berlin today Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this ...
plus

25.08.2009 – 10:01
EANS-News: Epigenomics AG: Clinical Study Shows Lead Biomarker for Lung Cancer also works in Blood
Biomarker mSHOX2 could accelerate diagnostic work-up of patients with suspected lung cancer Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics/Products Press release, Berlin, Germany, and ...
plus
12.08.2009 – 11:48
EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories, Inc.
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Licensing Agreements/Molecular diagnostics 12.08.2009 Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular ...
plus
12.08.2009 – 11:47
EANS-News: Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories
ARUP to commercialize laboratory-developed blood test based on Epigenomics' mSEPT9 biomarker to aid in the early detection of colorectal cancer Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies/cooperations/Molecular diagnostics Press Release, Berlin, Germany and Seattle, ...
plus
11.08.2009 – 08:32
EANS-News: Epigenomics AG Reports First Half 2009 Results
Key Figures . Revenue: EUR 2.1 million in H1 2009, up by 37% (H1 2008: EUR 1.5 million) . EBIT: EUR - 4.8 million in H1 2009, improved by 19% (H1 2008: EUR -5.9 million) . Net loss: EUR - 4.8 million in H1 2009, decreased by 15% (H1 2008: EUR -5.6 illion) . Liquid assets: EUR 12.1 million as of 30/06/2009 (31/12/2008: EUR 12.1 million) Highlights of the First Half 2009 . Significantly improved ...
plus
20.07.2009 – 10:01
EANS-News: DxS and Epigenomics Cross-License Technology for In Vitro Diagnostics
Both companies to use Scorpions® technology for diagnostic products based on DNA methylation Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies/cooperations/Molecular diagnostics Press Release, Manchester, UK, and Berlin, Germany, July 20, 2009 (euro adhoc) - DxS Ltd. ...
plus
30.06.2009 – 10:01
EANS-News: Epigenomics AG Certified for Diagnostic Product Development and Commercialization
ISO 13485 certification marks a milestone in Epigenomics' commercial strategy Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies/new product/Molecular Diagnostics Press release, Berlin, Germany, and Seattle, WA, USA, June 30, 2009 (euro adhoc) - Epigenomics AG (Frankfurt Prime ...
plus
25.06.2009 – 10:02
EANS-News: Epigenomics AG Presents Colorectal Cancer Blood Test at ESMO Conference
mSEPT9 biomarker facilitates innovative blood test for colorectal cancer PRESEPT Study for colorectal cancer screening with mSEPT9 well on track First European diagnostic laboratory to offer mSEPT9 testing on 1st July Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. new ...
plus
23.06.2009 – 10:01
EANS-News: Swiss Viollier AG First Laboratory in Europe to offer Epigenomics' Colorectal Cancer Blood Test
The Swiss private diagnostic laboratory will launch mSEPT9 blood testing service for colorectal cancer early detection on July 1, 2009 Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. new product/Molecular Diagnostics Press ...
plus
02.06.2009 – 11:01
EANS-News: Epigenomics AG reports progress in clinical development of its colorectal cancer blood test during Digestive Disease Week
mSEPT9 biomarker facilitates innovative blood test for colorectal cancer mSEPT9 data published in Clinical Chemistry PRESEPT Study for colorectal cancer screening with mSEPT9 well on track Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this ...
plus

29.05.2009 – 10:03
EANS-News: Epigenomics AG Presents Clinical Data from Prostate Cancer Prognosis Study at ASCO
Biomarker mPITX2 for prostate cancer prognostic application successfully validated First clinical laboratory in Germany to start offering mPITX2 testing service Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. new product/research/Molecular diagnostics Press release, Berlin, Germany ...
plus
26.05.2009 – 11:03
EANS-News: Novel German Research Alliance to Detect Precursors of Colorectal Cancer - Munich Technical University, Epigenomics AG and KVB to develop novel approaches to cancer prevention
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. research/new product/molecular diagnostics Berlin and Munich, Germany, May 26, 2009 (euro adhoc) - The German Federal Ministry of Education and Research will fund a clinical research ...
plus
13.05.2009 – 10:01
EANS-News: Epigenomics AG Receives Allowances for Key Patents in Europe
Patents cover biomarker mPITX2 for prostate and breast cancer indications Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. new product/molecular diagnostics Berlin, Germany, and Seattle, WA, USA, May 13, 2009 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular ...
plus
11.05.2009 – 08:33
EANS-News: Epigenomics AG Reports First Quarter 2009 Financial Results
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. finances/molecular diagnostics Berlin, Germany and Seattle, WA, U.S.A., May 11, 2009 (euro adhoc) - Key Figures . Revenue: EUR 1.24 million in Q1 2009, up by 36% (Q1 2008: EUR 0.92 million) . EBIT: EUR -2.31 million in Q1 2009, ...
plus
28.04.2009 – 09:02
EANS-News: Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Predictive Biosciences
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. cooperations/molecular diagnostics Berlin, Germany and Seattle, WA, U.S.A., (euro adhoc) - April 28, 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular ...
plus
31.03.2009 – 08:31
EANS-News: Epigenomics AG / Epigenomics AG Reports Financial Results for the Fiscal Year 2008
Successfully delivering on new partnering deals - PRESEPT clinical trial on track - Product launches expected in 2009 - Financials in line with latest expectations - Two successful financing transactions ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. balance/molecular diagnostics Press Release, ...
plus
25.03.2009 – 18:19
EANS-Adhoc: Epigenomics AG / Ad hoc (§15 WpHG): Epigenomics AG: Notice of Loss
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 25.03.2009 Berlin, Germany, - The Executive Board of Epigenomics AG notifies that using its due diligence it has to be assumed that using German GAAP HGB) accounting losses of more than half of the ordinary share capital ...
plus
18.03.2009 – 10:03
EANS-News: Epigenomics AG / Epigenomics AG Moves Lung Cancer Test into Development after Successful Clinical Evaluation
Test to aid in the diagnosis of lung cancer after positive CT findings ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. new product/companies/molecular diagnostics Berlin, Germany and Seattle, WA, U.S.A., (euro adhoc) - March 18, 2009 - ...
plus
11.03.2009 – 11:32
EANS-News: Epigenomics AG / Epigenomics AG to host Press Conference and Analyst Meeting for 2008 Annual Results
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/press conference Berlin, Germany and Seattle, WA, U.S.A (euro adhoc) - March 11, 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company will hold its ...
plus
25.02.2009 – 10:31
Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. cooperations/Molecular Diagnostics Berlin, Germany and Seattle, WA, U.S.A. (euro adhoc) - February 25, 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, today announced that it has entered into a ...
plus
12.02.2009 – 08:01
Epigenomics AG Successfully Places Shares at Premium in Capital Increase
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/Diagnostics Berlin (euro adhoc) - 12. February 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) successfully placed all 2,671,088 new shares that were issued in an increase of the share capital against contribution ...
plus
11.02.2009 – 18:04
euro adhoc: Restructuring & Recapitalisations / Ad Hoc (§15 WpHG): Epigenomics AG Increases Share Capital
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 11.02.2009 Berlin, Germany - Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) announces that the Executive Board and Supervisory Board have resolved today to increase the ...
plus

Précédent12345Suivant